Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2019-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2019
2019-05-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 7, 2019, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2019. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not "filed" for purposes of certain securities laws, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 3775 characters, which is relatively short and consistent with an announcement rather than a full earnings release. The content corresponds to an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER).
2019-05-07 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive lease agreement and the creation of a direct financial obligation related to that lease. It does not contain comprehensive financial statements or detailed financial performance data, nor is it an earnings release or annual/interim report. The document is a regulatory announcement of a significant event rather than a full report. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2019-05-03 English
DEF 14A
Proxy Solicitation & Information Statement
2019-04-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 7, 2019, by Aeglea BioTherapeutics, Inc. It announces updated Phase 1/2 clinical data and references a press release, oral presentation, and corporate presentation attached as exhibits. The document states that these materials are furnished and not filed, indicating this is a current report providing updates rather than a full financial report. The content focuses on Regulation FD Disclosure about clinical data and investor presentations, typical of an 8-K current report. The document length is 4090 characters, which is relatively short and consistent with an 8-K filing. Given these factors, the filing type is best classified as Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories such as earnings releases or annual reports.
2019-04-08 English
Regulatory Filings 2019
Regulatory Filings
2019-03-18 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.